Amgen Delivers Mixed Data For Rocatinlimab In Atopic Dermatitis, Uplizna In Myasthenia Gravis
Four Of Seven More AD Trials To Read Out Over Next Year
Rocatinlimab met its Phase III endpoints with results that appear uncompetitive with AD market leader Dupixent, while Uplizna may offer a compelling twice-yearly gMG treatment option.
